Drug intelligence / Profile preview

AZD2389 + quinidine

Development stage
Unknown
Lead developer
AstraZeneca
Modality
Small Molecules
Administration
Oral
01

Overview

AZD2389 + quinidine is an investigational combination of AZD2389, a novel small molecule, co-administered with quinidine, a known antiarrhythmic agent. The combination is under clinical study to assess the pharmacokinetics and safety of AZD2389 when given with quinidine in healthy participants. Quinidine is likely included to evaluate drug-drug interaction effects on the metabolism of AZD2389. AZD2389 is being developed by AstraZeneca, primarily for liver diseases such as advanced chronic liver disease and liver fibrosis. The precise mechanism of action of AZD2389 is not specified in current trial data, but participants with history of hypersensitivity to dipeptidyl peptidase 4 (DPP4) inhibitors are excluded, suggesting AZD2389 may involve DPP4 modulation[1][3][7].

Other names
azd2389 + quinidine
02

Targets

FAP (Fibroblast activation protein alpha)

Beyond the preview

Go deeper on AZD2389 + quinidine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD2389 + quinidine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call